Compare DuPont de Nemours Inc (DD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Viatris Inc — how do they compare? DuPont de Nemours Inc trades at $130.15 (market cap $17.89B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: DuPont de Nemours Inc and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Viatris Inc for 57 Days on average.
| DD | VTRS | |
|---|---|---|
Market Cap | $17.89B | $20.03B |
Volume | 816,409 | 14,109,977 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $18.27 |
52-Week Low | $92.49 | $9.74 |
Typical Hold Time | 89 Days | 57 Days |
Enterprise Value | $19.28B | $32.15B |
Dividend Yield | 1.81% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $130.00, down 0.82% on the day, with a neutral technical signal and mixed financial trends. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 contrast with a net loss of $779 million in 2025, though 2026 forecasts show a return to profitability. The company faces headwinds from PFAS litigation settlements and volatile cash flows, but innovation in areas like Tyvek and water technology supports long-term growth prospects.
The outlook for DD is cautiously optimistic, driven by secular growth in healthcare and water technologies, but weighed down by legal liabilities and margin pressures. Analyst consensus is bullish with a 58.54% buy rating, though the $95.00 price target suggests downside risk from current levels. Key risks include ongoing litigation costs and economic sensitivity in construction markets.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
